Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jamjoom Pharmaceuticals Factory Co's enterprise value is ﷼9,211 Mil.
Jamjoom Pharmaceuticals Factory Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ﷼554 Mil. Therefore, Jamjoom Pharmaceuticals Factory Co's EV-to-EBITDA for today is 16.61.
SAU:4015'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.75 Med: 24.47 Max: 36.2
Current: 16.39
During the past 8 years, the highest EV-to-EBITDA of Jamjoom Pharmaceuticals Factory Co was 36.20. The lowest was 15.75. And the median was 24.47.
SAU:4015's EV-to-EBITDA is ranked worse than 61.39% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.395
vs SAU:4015: 16.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Jamjoom Pharmaceuticals Factory Co (SAU:4015) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jamjoom Pharmaceuticals Factory Co's PE Ratio (TTM) for today is calculated as:
Jamjoom Pharmaceuticals Factory Co's share price for today is ﷼131.80.
Jamjoom Pharmaceuticals Factory Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼6.866.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co EV-to-EBITDA Chart
SAU:4015 vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jamjoom Pharmaceuticals Factory Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jamjoom Pharmaceuticals Factory Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jamjoom Pharmaceuticals Factory Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jamjoom Pharmaceuticals Factory Co's EV-to-EBITDA falls into.
Jamjoom Pharmaceuticals Factory Co's current Enterprise Value is ﷼9,211 Mil.
Jamjoom Pharmaceuticals Factory Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼554 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co (SAU:4015) has a EV-to-EBITDA of 16.61 as of Sep. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jamjoom Pharmaceuticals Factory Co. This is 32% below median its historical median of 24.47. Over the past decade, Jamjoom Pharmaceuticals Factory Co's EV-to-EBITDA has ranged from 15.75 to 36.20. According to the industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #458 out of 746 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Jamjoom Pharmaceuticals Factory Co's EV-to-EBITDA too high?
Jamjoom Pharmaceuticals Factory Co's current EV-to-EBITDA of 16.61 is 32% below median its 10-year median of 24.47. Over the past 10 years, this metric has ranged from a low of 15.75 to a high of 36.20. The Drug Manufacturers industry median EV-to-EBITDA is 12.40. Jamjoom Pharmaceuticals Factory Co's value of 16.61 is 34% above this industry median. Based on the distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #458 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jamjoom Pharmaceuticals Factory Co has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jamjoom Pharmaceuticals Factory Co's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #458 out of 746 companies for EV-to-EBITDA. This places Jamjoom Pharmaceuticals Factory Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.40. Jamjoom Pharmaceuticals Factory Co's value of 16.61 is 34% above this benchmark. Historically, Jamjoom Pharmaceuticals Factory Co's own EV-to-EBITDA has ranged from 15.75 to 36.20 over the past decade. While the company's 10-year median is 24.47 vs. the industry median of 12.40, Jamjoom Pharmaceuticals Factory Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.40, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jamjoom Pharmaceuticals Factory Co's current EV-to-EBITDA of 16.61 is 34% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jamjoom Pharmaceuticals Factory Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jamjoom Pharmaceuticals Factory Co's current EV-to-EBITDA is 16.61, which is 32% below median its own 10-year median of 24.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jamjoom Pharmaceuticals Factory Co stock overvalued right now?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co (SAU:4015) is currently considered Modestly Undervalued. The stock's GF Value™ is ﷼181.35, compared to a current price of ﷼131.80 — trading 27.3% below its estimated fair value. The current EV-to-EBITDA is 16.61, which is 32% below median its 10-year median of 24.47 and 34% above the Drug Manufacturers industry median of 12.40. Jamjoom Pharmaceuticals Factory Co's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jamjoom Pharmaceuticals Factory Co (SAU:4015), the current EV-to-EBITDA is 16.61 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jamjoom Pharmaceuticals Factory Co (SAU:4015) Overvalued in 2026?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co stock appears to be undervalued.
The current stock price of ﷼131.80 is trading 27.3% below its estimated GF Value™ of ﷼181.35.
GuruFocus considers Jamjoom Pharmaceuticals Factory Co to be Modestly Undervalued.
Key valuation signals for SAU:4015:
EV-to-EBITDA: 16.61 (32% below median its 10-year median of 24.47)
GF Value™: ﷼181.35 vs. price of ﷼131.80 (27.3% below fair value)
Industry Position: 34% above the Drug Manufacturers median (#458 of 746)
No single metric tells the full story. See the SAU:4015 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jamjoom Pharmaceuticals Factory Co is engaged in producing human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer and acidity, treatment of various skin infections, cancer diseases, eye drops and ointments and cosmeceuticals. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
94GF Score
Get the complete analysis for SAU:4015
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4015 has been successfully added to your 
